Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Stock Information for Nexera Energy Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nexera Energy Inc.

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
Cybin to Participate in the 2025 Psychedelic Science Conference
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.